Last reviewed · How we verify
Mirikizumab Reference
At a glance
| Generic name | Mirikizumab Reference |
|---|---|
| Also known as | LY3074828 |
| Sponsor | Eli Lilly and Company |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Mirikizumab Solution (LY3074828) in Healthy Participants (PHASE1)
- A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants (PHASE1)
- A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants (PHASE1)
- A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy Participants (PHASE1)
- A Study of Mirikizumab (LY3074828) Injection in Healthy Participants (PHASE1)
- A Study of Injections of LY3074828 in Healthy Participants (PHASE1)
- A Study of LY3074828 in Healthy Participants (PHASE1)
- A Study of Two Different Formulations of LY3074828 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mirikizumab Reference CI brief — competitive landscape report
- Mirikizumab Reference updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI